ArticleAdvanced healthcare materials2015
Monocyte-targeting supramolecular micellar assemblies: a molecular diagnostic tool for atherosclerosis.
Article in Advanced healthcare materials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 59 citations in OpenAlex.
- Oral delivery of nanomedicine for genetic kidney disease.PNAS nexus · 2024Article
- Biomimetic nanomedicines for precise atherosclerosis theranostics.Acta pharmaceutica Sinica. B · 2023Review
- Long-term, in vivo therapeutic effects of a single dose of miR-145 micelles for atherosclerosis.Bioactive materials · 2023Article
- Advances in imaging and treatment of atherosclerosis based on organic nanoparticles.APL bioengineering · 2022Review
- Surface-modified nanotherapeutics targeting atherosclerosis.Biomaterials science · 2022Review
- Advanced targeted nanomedicines for vulnerable atherosclerosis plaque imaging and their potential clinical implications.Frontiers in pharmacology · 2022Review
- Recent advances of natural and bioengineered extracellular vesicles and their application in vascular regeneration.Regenerative biomaterials · 2022Review
- Targeted polyelectrolyte complex micelles treat vascular complications in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Overcoming physiological barriers by nanoparticles for intravenous drug delivery to the lymph nodes.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Self-Assembled Peptide Amphiphile Nanofibers for Controlled Therapeutic Delivery to the Atherosclerotic Niche.Advanced therapeutics · 2021Article
- miR-145 micelles mitigate atherosclerosis by modulating vascular smooth muscle cell phenotype.Biomaterials · 2021Article
- CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation.Journal of controlled release : official journal of the Controlled Release Society · 2021Article
- The double-edged sword effect of macrophage targeting delivery system in different macrophage subsets related diseases.Journal of nanobiotechnology · 2020Article
- The effect of size, charge, and peptide ligand length on kidney targeting by small, organic nanoparticles.Bioengineering & translational medicine · 2020Article
- Collagenase-Cleavable Peptide Amphiphile Micelles as a Novel Theranostic Strategy in Atherosclerosis.Advanced therapeutics · 2020Article
- Hydroxyapatite-binding micelles for the detection of vascular calcification in atherosclerosis.Journal of materials chemistry. B · 2019Article
- S100A9-targeted tobacco mosaic virus nanoparticles exhibit high specificity toward atherosclerotic lesions in ApoEJournal of materials chemistry. B · 2019Article
- Mechanosensing and Mechanoregulation of Endothelial Cell Functions.Comprehensive Physiology · 2019Review
- EGFP-EGF1-conjugated poly(lactic-co-glycolic acid) nanoparticles, a new diagnostic tool and drug carrier for atherosclerosis.International journal of nanomedicine · 2019Article
- Shape Effects of Peptide Amphiphile Micelles for Targeting Monocytes.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Atherosclerosis is a multifactorial inflammatory disease that can progress silently for decades and result in myocardial infarction, stroke, and death. Diagnostic imaging technologies have made great strides to define the degree of atherosclerotic plaque burden through the severity of arterial stenosis. However, current technologies cannot differentiate more lethal "vulnerable plaques," and are not sensitive enough for preventive medicine. Imaging early molecular markers and quantifying the extent of disease progression continues to be a major challenge in the field. To this end, monocyte-targeting, peptide amphiphile micelles (PAMs) are engineered through the incorporation of the chemokine receptor CCR2-binding motif of monocyte chemoattractant protein-1 (MCP-1) and MCP-1 PAMs are evaluated preclinically as diagnostic tools for atherosclerosis. Monocyte-targeting is desirable as the influx of monocytes is a marker of early lesions, accumulation of monocytes is linked to atherosclerosis progression, and rupture-prone plaques have higher numbers of monocytes. MCP-1 PAMs bind to monocytes in vitro, and MCP-1 PAMs detect and discriminate between early- and late-stage atherosclerotic aortas. Moreover, MCP-1 PAMs are found to be eliminated via renal clearance and the mononuclear phagocyte system (MPS) without adverse side effects. Thus, MCP-1 PAMs are a promising new class of diagnostic agents capable of monitoring the progression of atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.